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Background: TMEM16A, also known as Anoctamin-1, is a calcium-activated chloride channel gene overexpressed in
many tumors. The role of TMEM16A in cancer is not completely understood and no data are available regarding the
potential tumorigenic properties of the multiple isoforms generated by alternative splicing (AS).
Methods: We evaluated TMEM16A AS pattern, isoforms distribution and Splicing Coordination (SC), in normal
tissues and breast cancers, through a semi-quantitative PCR-assay that amplifies transcripts across three AS exons,
6b, 13 and 15.
Results: In breast cancer, we did not observe an association either to AS of individual exons or to specific TMEM16A
isoforms, and induced expression of the most common isoforms present in tumors in the HEK293 Flp-In Tet-ON system
had no effect on cellular proliferation and migration. The analysis of splicing coordination, a mechanism that regulates
AS of distant exons, showed a preferential association of exon 6b and 15 in several normal tissues and tumors: isoforms
that predominantly include exon 6b tend to exclude exon 15 and vice versa. Interestingly, we found an increase in SC
in breast tumors compared to matched normal tissues.
Conclusions: As the different TMEM16A isoforms do not affect proliferation or migration and do not associate with
tumors, our results suggest that the resulting channel activities are not directly involved in cell growth and motility.
Conversely, the observed increase in SC in breast tumors suggests that the maintenance of the regulatory mechanism
that coordinates distant alternative spliced exons in multiple genes other than TMEM16A is necessary for cancer cell
viability.
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TMEM16A (also known as ANO1, DOG1, ORAOV2 or
TAOS2) is a member of the Anoctamin family of mem-
brane proteins, which consists of ten components (known
as TMEM16A-K or ANO1-10) that share a highly con-
served structure with eight transmembrane domains and
cytosolic amino- and carboxy-termini domains. In 2008,
three independent groups identified TMEM16A as a bona
fide Ca2+-activated Cl- channel (CaCC) essential for a var-
iety of physiological functions including neuronal and car-
diac excitation, olfactory and sensory signal transduction,
vascular tone and pain perception [1,2]. TMEM16A is* Correspondence: pagani@icgeb.org
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reproduction in any medium, provided the orexpressed in many tissues that are known to express
CaCCs: bronchiolar epithelial cells, pancreatic acinar cells,
proximal kidney tubule epithelium, retina, dorsal root
ganglion sensory neurons, and sub- mandibular gland
[3-5]. In addition to epithelia, TMEM16A is robustly
expressed in interstitial cells of Cajal, which are respon-
sible for generating pacemaker activity in smooth muscle
of the gut [6-8].
TMEM16A is a sensitive biomarker for the diagnosis
of gastrointestinal stromal tumors (GISTs) and it is
overexpressed in several cancers including urinary bladder
cancer, esophageal cancer, prostate cancer, breast cancer,
head and neck squamous cell carcinoma (HNSCC), para-
thyroid tumors and ovarian tumors [9-13]. However, its
role in tumor cell proliferation and migration is not com-
pletely understood. In cellular models, TMEM16A hastd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Ubby et al. Molecular Cancer 2013, 12:75 Page 2 of 13
http://www.molecular-cancer.com/content/12/1/75been reported to positively affect cell proliferation and/or
migration [9,12-16]. Conversely, Wang et al. [17] showed
a negative effect of cell proliferation by preventing cell
cycle transition from the G0/G1 phase to the S phase via
inhibition of cyclin D1 and cyclin E expression [17]. Sev-
eral mechanisms have been reported that associate
changes in Ca2+-dependent channel activities with its
tumorigenic potential are unknown: prevention of cell
cycle transition from the G0/G1 phase to the S phase via
inhibition of cyclin D1 and cyclin E expression [17], acti-
vation of MAPK kinases with promotion of ERK1/2 and
cyclin D1 activation [9] and activation of EGFR and
CAMK signalling [13]. In general, similar to other chan-
nels such as Ca(2+)-activated K(+) channels and voltage-
gated Cl(−) or K(+)channels, TMEM16A might affect cell
motility and proliferation though dynamic changes in the
cellular volume [18-21].
Alternative splicing of TMEM16A can generate mul-
tiple protein isoforms with different electrophysiological
properties affecting the voltage and Ca2+-dependence of
the channel [22]. The most important AS occurring on
TMEM16A transcripts consist in skipping/ inclusion of
three exons 6b, 13 and 15. Other minor splicing events
affecting exon 1, 10, 14 and 18 have also been reported,
leading to the formation of several TMEM16A tran-
scripts [23,24]. We have previously reported the relative
percentage of inclusion of each exon relative to the total
amount of TMEM16A transcripts showing that in sev-
eral normal human tissues, transcripts that predomin-
antly include exon 6b, also tend to lack exon 15 in the
same mature transcripts and vice-versa [22]. However,
the relative proportion of each isoform that take into ac-
count the real association between the AS events on the
same transcript is unknown.
In the TMEM16A gene and thus on the nascent tran-
scripts, the three exons, 6b, 13 and 15 are located rela-
tively far apart (exons 6b and 15 are located at 50 kb).
Comparison of data from transcript sequencing efforts,
EST/cDNA sequences and microarray profiling experi-
ments have provided evidence for AS coordination be-
tween multiple exons within a single gene [25-28]. Indeed,
distant alternative splicing events on the same gene can be
correlated, through a mechanism known as intragenic
Splicing Coordination (SC) [27,29,30]. The presence of
multiple splice variants on the same transcript, as found
in TMEM16A, can highly increase its potential to generate
multiple transcripts. However, as AS events are generally
analyzed separately through PCR amplification of short re-
gions, this correlation is difficult to establish and have not
been explored in tumors. The mechanism that regulates
the coordinate selection of AS events in the same gene in-
volves both cis-acting regulatory elements present on the
nascent transcripts and Polymerase II -dependent tran-
scriptional elongation [27].In the present study, using a PCR-assay that amplifies
transcripts across the three AS exons, we found that
TMEM16A AS of exons 6b and 15 are coordinated in
several normal tissues and that this coordination in-
creases in breast tumors. AS of individual exons was not
altered in breast tumor and overexpression of the
TMEM16A isoforms in a controlled cellular system had
no effect on proliferation and migration. These results
suggest that TMEM16A expression and splicing does
not confer a positive general effect on cell growth and
motility. The unexpected increase of SC in breast tu-
mors suggest that cancer cells maintain the regulatory
mechanism that coordinates distant alternative spliced
exons on the same transcript, a process that, by acting
on multiple genes, may be important in tumor cell
viability.
Results
Identification of TMEM16A mRNA isoforms in normal
human tissues
To study the expression of the three TMEM16A AS exons,
we previously used RT-PCR analysis, with primers that
amplify each exon separately [22]. In normal human tis-
sues, we observed significant changes in AS for exons 6b
and 15, whereas exon 13 was minimally skipped only in
two tissues (brain and skeletal muscle). In addition, several
normal adult human tissues that predominantly include
exon 6b tend to exclude exon 15 from the mature tran-
script [22]. To assess the relative abundance of the
TMEM16A isoforms, we set up a denaturing capillary
electrophoresis of fluorescent-5′ end labelled RT-PCR
(Figure 1A). In this assay, the long-range PCR amplifies
TMEM16A transcripts that include the three AS events.
Due to the possible combinations of the three alternatively
spliced exons 6b, 13 and 15, eight mRNA isoforms of dif-
ferent molecular size are expected to originate from the
long range PCR (Figure 1B). The assignment of each peak
to a specific splice variant was based upon comparison
with standard molecular weight (MW) markers and direct
sequencing of the bands eluted from the agarose gels. In
the majority of tissues, we detected four splice variants of
725 bp, 791 bp, 803 bp and 869 bp, which correspond to
6b-13 + 15-, 6b + 13 + 15-, 6b-13 + 15+ and 6b + 13 + 15+
isoforms, respectively (isoforms 2, 4, 6 and 8 in Figure 1B
and Additional file 1: Figure S1). Figure 1C illustrates a
typical electropherogram of two tissues that contains these
four isoforms. As expected and previously reported [22],
we observed the appearance of additional bands of 779 bp
and 713 bp (Figure 1D), which originate from exon 13
skipping and correspond to 6b + 13-15- and 6b-13-15-
isoforms respectively (isoforms 1 and 3), in only two tis-
sues, namely brain and skeletal muscle. The two isoforms
4 and 5, that correspond to 6b + 13+ 15- and 6b- 13- and
15+ could not be clearly distinguished by size (791 bp vs
Figure 1 Identification of TMEM16A isoforms in normal adult human tissues through capillary electrophoresis. A, schematic representation of
the TMEM16A mRNA showing the position of the AS exons (black boxes), and the oligonucleotide used in RT-PCR experiments. RNA was amplified
with 803DFAM and 1894R primers. B, cartoon indicating the eight possible TMEM16A transcript variants as a result of combination of exon 6b, 13 and
15 inclusion and/or exclusion. The expected sizes of RT-PCR products are indicated on the right. C, typical electrophoregram of the RT-PCR products,
evaluated by capillary electrophoresis of tissues that express isoforms with exon 13 inclusion. Each peak corresponds to the isoforms indicated in B.
D, typical electrophoregram of the RT-PCR products of tissues that express the isoforms without exon13. The identity of the bands was verified by
directed sequencing.
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the samples where exon 13 is completely included,
which represent the majority of tissues, they corresponds
to band 4 only.The percentage of each isoform was calculated as the
area under the peaks, and Figure 2 shows the pattern of
expression of the four major TMEM16A isoforms in 20
human normal adult tissues. The different peak height
Figure 2 Quantification of TMEM16A isoforms in normal adult human tissues. TMEM16A isoforms in 20 normal adult human tissues were
separated using a capillary electrophoresis system as described in Figure 1 and percentages were determined from the total area of each peak.
Data are expressed as mean ± SD of three independent experiments. *, brain and skeletal muscle showed additional minor 13- isoform, not
reported in the graph. Ad = Adipose; Bl = Bladder; Br = Brain; Cer = Cervix; Col = Colon; Eso = Esophagus; He = Heart; Kid = Kidney; Liv = Liver;
Lu = Lung; Ov = Ovary; Pla = Placenta; Pro = Prostate; Mus = Skeletal Muscle; Int = Small Intestine; Spl = Spleen; Tes = Testes; Thym = Thymus;
Thyr = Thyroid; Tra = Trachea.
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pression levels of TMEM16A in the different tissues.
The three most represented isoforms identified were 6b-
13+ 15-, 6b + 13 + 15- and 6b-13+ 15+. Thus from this
we can infer with approximation the tissue specific ex-
pression. The relative proportion of these isoforms var-
ied significantly between tissues: for example, in lung
6b-13+ 15- and 6b-13+ 15+ were the most expressed
whereas in liver and thyroid tissues, 6b + 13 + 15- was
more prevalent, representing approximately 95% and
80%, of the total transcripts respectively (Figure 2). The
isoform that contains all the three exons, 6b + 13+ 15+
was present in a lower amount in all samples. To verify
that in our experimental conditions, the long range PCR
does not preferentially results in amplification of se-
lected isoforms, we compared the percentage of exon in-
clusion calculated with the long range PCR with the
percentage obtained through amplification of individual
exons (Additional file 2: Figure S2A). Results shown in
Additional file 2: Figure S2B, exhibited a significant cor-
relation between the percentages of exon 6b and 15 in-
clusions calculated with the two PCR amplification
methods.
TMEM16A alternative splicing of individual exons and of
specific isoforms does not change in breast tumors
To explore the role of the different TMEM16A isoforms
in tumors, we next analyzed 18 breast tumors and in
their corresponding normal breast tissues obtained from
the same surgical specimen. The histological andreceptor status of the tumors shown in Additional file 3:
Table S3 and the absence of tumor cells in the controls
were verified by histological analysis. Expression of
TMEM16A isoforms in the 36 paired tumor-normal
breast tissues was evaluated by RT-PCR amplification of
transcripts across the three AS events as done for the
normal human tissues (Figure 1). All the samples
showed four transcripts of 725 bp, 791 bp, 803 bp and
869 bp, which correspond to 6b-13 + 15-, 6b + 13 + 15-,
6b-13 + 15+ and 6b + 13 + 15+ isoforms respectively
(isoforms 2, 4, 6 and 8 in Figure 1B). No band with skip-
ping of exon 13 was detected. The data were analyzed by
considering the percentage of inclusion of each exon on
the total transcript (Figure 3A) and evaluating individu-
ally the different TMEM16A isoforms (Figure 3B). In the
normal breast, exon 6b, 15 and 13 were present in ap-
proximately 40%, 10% and 100% of the TMEM16A tran-
scripts respectively and these percentages did not
change significantly in the tumors (Figure 3A). Similarly,
the analysis of the distribution of the four mRNA
isoforms showed no significant differences between the
normal samples and the tumors (Figure 3B). Most of the
transcripts in both cases corresponded to 6b- 13+ 15-
and 6b + 13+ 15- isoforms (40-50%). Approximately 10%
of transcripts correspond to 6b- 13+ 15+ isoform and
5% to the isoform that include all the exons (6b + 13 +
15+). The scatter of the standard deviation (SD) in
tumor samples was increased in comparison to normal
breast tissues, indicating a higher variability of the four
isoforms distribution in cancer. All together these results
Figure 3 TMEM16A alternative splicing in human normal and cancer breast tissues. A, individual analysis of the three alternatively spliced
exons, 6b, 13 and 15, in normal and tumor breast tissues. The percentage is expressed as means ± SD, based on at least three independent
capillary electrophoresis analyses. B, TMEM16A isoforms profiles in normal and tumor breast tissues. The percentage is expressed as means ± SD,
based on at least three independent capillary electrophoresis analyses.
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derived isoforms are associated to breast tumors.
Overexpression of TMEM16A isoforms in HEK293 cells do
not affect cell migration and cell proliferation
To determine the possible role of the different TMEM16A
isoforms on migration and proliferation, we generated
stable clones in HEK293 Flp-In cells. We selected the four
most expressed isoforms detected in breast tumor samples
(Figure 3B) and the additional isoform 6b + 13- 15-
present in normal brain and skeletal muscle that lacks
exon 13 (Figure 1). In the HEK293 Flp-In Tet-ON system,
the presence of a unique copy of the transgene at the iden-
tical chromosomal site and driven by the inducible tetra-
cycline (Tet) promoter, allow a precise and comparable
evaluation of the biological properties of the different
TMEM16A isoforms. In all recombinant clones, Tet
addition induced expression of the corresponding TMEMisoform (Additional file 4: Figure S4). To assess
TMEM16A channel activity, we used the halide-sensitive
yellow fluorescent protein (HS-YFP) assay [3]. HEK293
cells transfected with the various TMEM16A isoforms
responded to tetracycline treatment with a very large
Ca2+-activated anion transport activity (Additional file 5:
Figure S5). In contrast, control cells treated under the
same conditions showed virtually no anion transport. To
evaluate the effect of these TMEM16A isoforms on cell
migration, we performed wound-healing assay. Confluent
HEK293 cells monolayer (two for each isoform) were
wounded with a sterile pipette tip (scratch assay) and
wound healing (re-closure of the scratch) was followed
by time lapse microscopy. Cells were incubated in the
presence or absence of tetracycline for 72 h. Clones ex-
pressing the different TMEM16A isoforms (Figure 4A)
did not show any significant difference in their capacity
to migrate into the wounded area compared to the
Figure 4 Cell migration and proliferation assay of TMEM16A variants. A, Representative images of wound healing in a scratch assay with
inducible expression of TMEM16A variants in HEK293 cells cultured with (Tet+) or without (Tet−) tetracycline (0.1 μg/ml). Original magnification,
4x. (Scale bars: 5 μm). B, Quantification of the fraction of the wound that remains uncovered by the migratory cells as a function of time for cell
treated with (Tet+) or without (Tet−). C, Cellular proliferation assay, BrdU staining of cells expressing TMEM16A variants (treated without or with
tetracycline). Data represent the % of BrdU+ cells and are the mean ± SD of three independent experiments.
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alone did not affect the percentage of migration between
each clone and between the different clones (Figure 4B).
We next evaluated whether overexpression of the
TMEM16A isoforms could affect cell proliferation. For
this purpose, we determined the incorporation of BrdU
in untreated and Tet- treated HEK293 Flp-In Tet-on
cells. We did not observe any significant difference in
the percentage of BrdU positive cells among the different
isoforms nor relative to the control cells (Figure 4C).
Splicing Coordination of TMEM16A AS is higher in breast
tumors
To evaluate the relationship between the two major AS
events on the same transcript and the presence of apossible intragenic Splicing Coordination (SC), we com-
pared the percentage of exon 6b inclusion in transcripts
that either included exon 15 or not. Significant differ-
ences in these percentages were considered as indicative
of the presence of TMEM16A isoforms in which the two
AS events are coordinated. The principle of the analysis
along with a graphic representation of the distribution of
the TMEM16A isoforms in two representative normal
tissues, cervix and adipose (a positive and a negative
case of coordination, respectively) is shown in Figure 5.
In these two examples, the overall percentage of exon 6b
inclusion is similar in cervix (23%) and in the adipose
tissue (20%) (lane 1, in Figure 5A). However, the distri-
bution of the exon 6b abundance in 15+ and 15- tran-
scripts was different between them. In fact, considering
Figure 5 Splicing coordination of TMEM16A mRNA isoforms in normal adult human tissues. A, example of a positive (cervix) and a negative
(adipose tissues) case of SC. The top of the panel shows the percentage of exon 6b inclusion in transcripts that include or exclude exon 15. Lane 1:
percentage of exon 6b inclusion considering all the four isoforms. Lane 2: percentage of exon 6b inclusion in the isoforms that contain only exon 15.
Lane 3: percentage of exon 6b inclusion in the isoforms that lacks exon 15. The identity of the isoforms considered in each calculation is depicted
below each lane. B, Percentage of exon 6b inclusion in transcripts that contain or lack exon 15. Quantification of exon 6b inclusion associated to exon
15 inclusion or exclusion in 18 normal adult human tissues. Statistically analysis was performed using paired Student’s t-test (*p < 0.05; p < 0.01**;
p < 0.001***). Ad = Adipose; Bl = Bladder; Cer = Cervix; Col = Colon; Eso = Esophagus; He = Heart; Kid = Kidney; Liv = Liver; Lu = Lung; Ov = Ovary;
Pla = Placenta; Pro = Prostate; Int = Small Intestine; Spl = Spleen; Tes = Testes; Thym = Thymus; Thyr = Thyroid; Tra = Trachea.
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responding level of inclusion of exon 6b was reduced to
13% in cervix but not in adipose tissue. Similarly, in
transcripts without exon 15 (lane 3), the inclusion of
exon 6b increased to 34% in cervix but did not change
in adipose tissue. Thus, even if the total percentage of
exon 6b was similar in the two tissues, only one (i.e.Cervix) showed some degree of splicing coordination.
The analysis showed that exon 6b has a preferential as-
sociation with transcripts in which exon 15 is skipped
and vice versa. The comparison of exon 6b inclusion in
transcripts that included exon 15 to transcript without it
in 18 normal tissues showed that the two AS exons 6b
and 15 were coordinated in 14 out of them.
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Kidney, Liver, Ovary, Placenta, Prostate, Small Intestine,
Spleen, Testes, Thyroid and Trachea, although Adipose,
Esophagus, Heart, Lung, and Thymus tissues were not
coordinated (Figure 5B). The analysis considering the
distribution of exon 15 inclusion associated to exon
6b isoforms gave comparable results (Additional file 6:
Figure S6).
Next, we evaluated the TMEM16A splicing coordin-
ation in mRNA derived from normal and tumor breasts
samples. This analysis revealed that in 9 out of 18 nor-
mal breast tissues (50%), the two AS events were coordi-
nated indicating the presence of an individual variability.
Interestingly, the intragenic splicing coordination was
present in 15 breast tumors (84%) (Figure 6) and this in-
crease in splicing coordination is due to the fact that
6 normal breasts that were not coordinated turn to
be coordinated in the corresponding cancer tissues
(Additional file 7: Figure S7). Thus, in TMEM16A tran-
scripts derived from normal breast, the exon 6b and 15
showed evidence of splicing coordination in 50% of the
samples and this percentage increase to 84% in tumors.
Discussion
In this paper, we have evaluated the potential role in
breast cancer of the different TMEM16A isoforms gen-
erated through alternative splicing. The analysis of the
alternative splicing pattern in vivo in breast tumors and
the functional analysis of the isoforms overexpressed in
a cellular model strongly suggest that the TMEM16A
Ca2+-dependent Cl- channel activities are not directly in-
volved in tumorigenesis. More precisely, the lack of ef-
fect on HEK293 growth and motility indicates that, if
TMEM16A has a role on cancer progression, it is not
due to a general effect on the regulation of cell cycle and
migration, as previously proposed [9,12-15]. However,
this does not exclude that TMEM16A has a more
cancer-specific role that is relevant to tumor growth
in vivo. On the other hand, in TMEM16A transcripts de-
rived from several normal tissues and breast tumors,Figure 6 Alternative splicing Coordination of TMEM16A in normal and
breasts and corresponding 18 tumors.inclusion/exclusion of the two distant alternatively
spliced exon 6b and 15 is not independent but occur in
a coordinated manner on a single transcript. As this spli-
cing coordination is significantly increased in breast tu-
mors, the regulatory mechanism that coordinates distant
alternative spliced exons on the same transcript is
maintained in these cells. We speculate that mainten-
ance of the mechanisms that control SC is necessary for
regulation of AS events in other genes directly involved
in tumor cell viability.
Several studies have associated TMEM16A expression
with cancer [9,31-33]. However, as tumors may originate
from cells that normally express TMEM16A, like GIST,
which is thought to derive from the interstitial cells of
Cajal [33,34], it is not clear if this channel is just an asso-
ciated marker or if it directly promotes tumorigenesis. In
addition, the mechanism that associates its Ca2+-
dependent Cl- activity to cellular proliferation is unclear,
and several studies reported contradictory effects on pro-
liferation and/or migration. In basilar smooth muscle cells,
where TMEM16A is abundantly expressed, its down-
regulation promotes proliferation and accordingly restor-
ation of TMEM16A activity was suggested to be beneficial
on hypertension-associated cardiovascular disease such as
stroke [17]. On the contrary, other studies reported that
TMEM16A promotes cell migration alone [35] or both
proliferation and migration [9,12,14,15]. In xenografts, loss
of TMEM16A through siRNA-mediated silencing was
reported to inhibit tumor growth [9,13]. As a result of this
positive effect on proliferation, and in contrast to the ef-
fect on smooth muscle cells [17], the therapeutic inhib-
ition of TMEM16A activity was proposed for the
treatment of cancers [9,13]. In this study, the analysis of
the different TMEM16A isoforms generated through AS
in vivo in breast cancer and in a controlled cellular model,
does not support a direct role of the major TMEM16A
isoforms in tumorigenesis. The evaluation of the different
functional properties of isoforms derived from AS is not
an easy task, in particular if referred to migration and pro-
liferation. To avoid clonal variability that can affectbreast cancer tissues. Analysis of SC was performed in 18 normal
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grated and site of integration, we used the inducible
HEK293 Flp-In Tet-ON system and the results clearly
show that the TMEM16A isoforms per se are not suffi-
cient to promote or inhibit proliferation and migration
(Figure 4). Even if our result does not support a direct role
of TMEM16A, the different isoforms might indirectly
affect proliferation and migration in a cell-type specific
manner. Accordingly, to affect proliferation and/or migra-
tion, TMEM16A expression would require expression of
additional factors, and this association could be at the
basis of the contradictory effects reported in different cell
types. This cell type specificity might be critical for the de-
velopment of therapeutic strategies, as different patho-
logical conditions and target cells may differently respond
to inhibition or restoration of the TMEM16A activity, as
previously reported [9,13,17]. The HEK293 Flp-In Tet-ON
system we have developed here, expressing the different
isoforms in a regulated manner, can represent an interest-
ing model to identify, with a high-throughput screening
method, those factors that not only promote or inhibit
proliferation in a TMEM-dependent manner but also po-
tential AS-specific networks.
An interesting and novel aspect of our study is the
identification in several normal tissues of TMEM16A SC
and the observation that this coordination increases in
breast tumors (Figure 6). In common with ~ 25% of hu-
man genes, TMEM16A has more than one alternative
splicing possibility and accordingly can generate several
isoforms. Through a mechanism known as intragenic
splicing coordination, [27,28,36] the association between
alternative spliced events is not random, as we have
found for exon 6b and 15 in TMEM16A. In normal
breast, approximately 50% of samples showed SC, which
increased to 84% in tumors. Normal mammary glands
express TMEM16A [37-39] and the individual hormonal
status might have an important effect on its AS pattern
and SC thus explaining the variability observed in nor-
mal tissues. In several genes, hormones modulate AS
[40,41] but the effect on splicing coordination is un-
known. Through histological evaluation, we do not have
evidence of the presence of tumor cells in normal sam-
ples, but normal glands showed a variable relative abun-
dance of different cell types (like epithelial, stromal and
adipocytes) and this might also contribute to the individ-
ual variability.
The fact that the expression of the two AS exons 6b
and 15 is coordinated in the majority of TMEM16A
transcripts derived from tumors (84%), suggest that can-
cer progression is not associated with a relaxation of this
phenomenon. The mechanisms underlying splicing co-
ordination are largely unknown. Fibronectin (FN) [27]
and slo-1 BK potassium channel [30] are well-studied
examples of genes with intragenic AS coordination. Inthese cases, mutations that affect one AS exon had a
profound effect on the other AS events, with both 5’ to
3’ polarity or bi-directionality for FN and Slo-1, respect-
ively. In addition, proper coordination of intragenic al-
ternative splicing has been found essential for normal
physiology of the slo-1 gene in vivo in Caenorhabditis
elegans [30]. Based on this evidences a mechanism that
lead to preferential expression of given alternate exon
combination was engaged. Recruitment of splicing fac-
tors with direct interactions between the RNA-protein
complexes from distinct splice sites, RNA secondary
structure determinants and changes in Pol II elongation
or processivity have been suggested to be involved
[27,30]. Another interesting hypothesis to explain intra-
genic AS coordination might involve the formation of
chromatin loops. Chromatin loops have been reported
to physically link promoters to the end of the gene in
order to facilitate Pol II-dependent transcription [42-45].
These loops can also occur in introns, as demonstrated
for the 85-Kb long BRCA1 gene in human cell lines and
in mouse mammary tissues [31]. Interestingly, these
loops change upon estrogen stimulation and during lac-
tational development [31]. Thus it is possible that loops
that put in contact distant alternatively spliced regions
on the same gene might have a role in splicing coordin-
ation and possibly regulated by hormonal status. In this
manner, Pol II engaged in transcription at different AS
exons might physically communicate with reciprocal in-
fluence on the corresponding splicing decisions. This
event might be still operative in tumor cells in order to
preserve cancer viability. More deep molecular studies
are required to unravel the basic mechanism of intra-
genic splicing coordination and understand their role in
cancer.
What could be the advantage of a tumor cell to main-
tain an intragenic splicing coordination? As none of the
TMEM16A isoforms directly affect proliferation or mi-
gration (Figure 4), it is possible that during tumorigen-
esis the cell would have to maintain active and efficient
the mechanism involved in splicing coordination. This
might not be specifically useful for the TMEM16A ex-
pression but for coordinating splicing of other genes dir-
ectly involved in proliferation or apoptosis such as CD44
gene, Ron gene or FGFR2 gene [46-49].
In conclusion, this study has improved our under-
standing of TMEM16A splicing coordination with the
identification and characterization of a non-random dis-
tribution of the mRNA isoforms in normal adult human
breast tissues and tumor.
In this context, the maintenance of splicing coordin-
ation will be required for preventing a massive transcript
alteration that will lead to cell death and thus the study of
the basic mechanism involved might be useful for the
identification of novel targets for therapeutic intervention.
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Human normal and primary tissue samples
Surgically resected tissue samples were obtained under
the General Surgery, “Presidio Ospedaliero di Gorizia,
Italy approved by the local Ethics Committee. Primary
breast tumors were obtained with the appropriate in-
formed consent. Normal breast tissues and correspond-
ing breast tumors were separated at the time of excision,
and conserved in RNA Later (Ambion Inc) at – 20°C.
The total RNA was extracted using TRIreagent solution
(Ambion) followed by an additional cleaning step (RNeasy;
Qiagen). RNA was quantified using the Nanodrop spec-
trophotometer instrument (Thermo Scientific) and quality
routinely verified on denaturing agarose gels. Normal
breast tissues and tumors were classified according to
standard histological evaluations, receptor and pro-
liferation markers as reported in Additional file 3:
Table S3.
Analysis of TMEM16A mRNA Splicing isoforms
One μg of total RNA derived from ductal and lobular
epithelial breast tumors and normal breast samples and
one μg of total RNA derived from 20 human tissues
(First Choice Human Total RNA Survey Panel; Ambion)
was retro-transcribed in standard conditions and ampli-
fied by PCR with a set of primers specific for each alterna-
tively spliced exon: for exon 6b, the sense and antisense
primers were 803DFAM and 1385R, 5′-[6FAM]CGGAGC
ACGATTGTCTATGA and 5’- GGGCCATGAAGACAG
AGAAG, respectively, for exon 13, 1368DFAM and 1525R,
5′-[6FAM]TCTCTGTCTTCATGGCCCTC and 5’-CTCC
AAGACTCTGGCTTCGT, respectively, and for exon 15,
1506DFAM and 1894R, 5′-[6FAM]ACGAAGCCAGAGTC
TTGGAG and 5′-GAACCGATCTCTCCATGTCAGCT
TCA, respectively. Conditions for PCR were the following:
94°C for 5 min for the initial denaturation; 94°C for 45 s,
58°C for 45 s, and 72°C for 1 min for 35 cycles; and 72°C
for 10 min for the final extension. Semi-quantitative ana-
lyses of the TMEM16A isoforms were performed by Capil-
lary Electrophoresis (CE) at the BMR genomics, Italy
(http://www.bmr-genomics.it/). The relative amount of
each mRNA isoform was calculated based on the cor-
rected integrated area of each peak and size was calculated
using Rox1000BV marker (Bmr-Genomics). For Spicing
Coordination experiments, RNA extracted from human
adult normal tissues, normal and tumor breast tissues
were amplified using a labelled fluorescent 803DFAM 5′-
[6FAM]CGGAGCACGATTGTCTATGA and 1894R
primer 5′-GAACCGATCTCTCCATGTCAGCTTCA. Con-
ditions for PCR were the following: 94°C for 3 min for the
initial denaturation, 94°C for 45 s, 56°C for 45 s, 72°C for
1 min and 72°C for 10 min for the final extension. 1 μL of
the PCR product was dehydrated at the temperature of
60°C for 20 min and sent for the CE analysis. The resultsare expressed as mean ± S.D. of three independent experi-
ments done in duplicate.
TMEM16A Expression vectors and cell culture
The TMEM16A isoforms 6b-13 + 15-, 6b + 13 + 15+ 6b +
13 + 15-, and 6b + 13-15- were obtained form correspond-
ing plasmids [3,22]. TMEM16A (6b-13 + 15+) was gener-
ated from the TMEM16A (6b + 13 + 15+, and 6b-13 + 15-)
constructs by RT-PCR (forward) 5′-TGCGACAAGACC
TGCAGCTACTGG-3′ and (reverse) 5′-TGTAGGAATT
CAAACTTCAGCAG-3′ and cloned in the PstI and EcoRI
of pBS(6b-13 + 15-) to generate pBS(6b-13 + 15+). Subse-
quently, pBS(6b-13 + 15+) was digested with EcoRI and
BamHI and cloned in the corresponding sites of
pcDNA3.1 to generate pcDNA3.1(6b-13 + 15+). All the
coding sequences for TMEM16A (6b + 13-15-, 6b + 13 +
15-, 6b + 13 + 15+, 6b-13 + 15-, and 6b-13 + 15+) were
cloned in the pcDNA5 FRT/TO plasmid (Invitrogen).
Stable expression of TMEM16A variants was achieved by
Flp-recombinase-mediated recombination in HEK293 Flp-
In cells (Invitrogen) followed by hygromycin B selection
(InvivoGen). Each TMEM16A-expressing vector that
expresses the Flp-recombinase (Invitrogen) was co-
transfected with Effectene transfection reagent (Qiagen)
and selected with a concentration of 200 μ g/ml
hygromycin B. Individual clones were obtained by limited
dilution. Induction of TMEM16A isoforms expression was
achieved with 0.1 μg/ml tetracycline (Sigma). Cells were
grown in DMEM-Glutamax-I media (GIBCO) supple-
mented with 5% fetal bovine serum (EuroClone).
In vitro wound healing assay
Cell mobility was assessed using a scratch wound healing
assay. HEK293 stable cells were plated (5 × 105 cells) in 6-
well plates, coated with poly-D-lysine (1 mg/ml, Sigma).
0.1 μg tetracycline (Sigma) was added one day after plat-
ing. Confluent monolayers (24 h after tetracycline induc-
tion) were scraped with 200 μl disposable plastic pipette
tips. Pictures were taken every 24 h with a confocal micro-
scope (Leica TCS-SL) (4 × amplification). The distances
between the wound edges were measured using Graphic-
Converter software. These experiments were carried out
in triplicates.
Immunofluorescence
TMEM16A-inducible HEK293 cells were grown on 6-
well plate and cultured in the presence or absence of
0.1 μg/ml tetracycline for 72 hrs to induce TMEM16A
isoform expression. The cells were fixed with Bouin so-
lution (Sigma-Aldrich) for 10 minutes at room
temperature, washed twice in PBS, and incubated with
blocking solution (1% BSA and 1% PBS) for 2 hrs at
room temperature. The cells were then stained overnight
at 4°C with primary monoclonal antibody against
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(Sigma-Aldrich) in 1%PBS-BSA. Cells were washed with
PBS and incubated for 2 h with the respective secondary
antibodies conjugated to Alexa Fluor-488 (Life Tech-
nologies). This was rinsed again in PBS, before viewing
cells under a laser-scanning microscope LSM 5 EX-
CITER (Carl Zeiss MicroImaging).
HS-YFP assay
HEK-293 cells, plated in 96-well microplates, were tran-
siently transfected with a plasmid coding for the halidse-
sensitive yellow fluorescent protein (HS-YFP) as previ-
ously described [3]. After 24 hours, cells were treated
with tetracycline to induce TMEM16A expression. At
the time of assay, cells were washed two times with
100 μl PBS (137 mM NaCl, 2.7 mM KCl, 8.1 mM
Na2HPO4, 1.5 mM KH2PO4, 1 mM CaCl2, and 0.5 mM
MgCl2; pH = 7.4) and incubated for 30 min with 60 μl
PBS. Cells were transferred to the stage of a fluorescence
microscope equipped with excitation and emission filters
for the yellow fluorescent protein. Cell fluorescence in
each well was continuously acquired with a CoolSNAP
HQ2 camera before and during addition of 165 μl of
modified PBS (Cl- replaced by l-; final l- concentration in
the well: 100 mM) also containing 1 μM ionomycin.
Fluorescence cell traces were normalized to the initial,
background-subtracted, fluorescence. TMEM16A activity
was calculated from the maximal rate of fluorescence
quenching caused by l- influx.
Cell proliferation assay
TMEM16A-inducible HEK293 cells, were grown on 96-
well plate and cultured in the presence or absence of
0.1 μg/ml tetracycline. After 24 hours, cells were incu-
bated with EdU (Invitrogen). 30 minutes after EdU
addition, cells were washed once in PBS, fixed in PFA
4%, for 15 min, permeabilized with 0.5% Triton X-100 in
PBS solution for 10 min. EdU detection was carried out
using Click-iT EdU Cell Proliferation Assay (Invitrogen).
Statistical analysis
A statistical analysis was performed on the investigated
groups of data using the Student’s t-test and the Fisher’s
exact test.
Additional files
Additional file 1: Figure S1. Exon-Exon junctions of TMEM16A
isoforms. Nucleotide sequences of TMEM16A cDNA isoforms expressed in
human adult normal tissues, breast and tumor breast tissues.
Additional file 2: Figure S2. Correlation between the percentage of
exon 6b and 15 inclusion calculated in short and long RT-PCR
amplifications in normal adult human tissues. A, schematic representation
of the TMEM16A mRNA showing the position of the AS exons (black
boxes), and the oligonucleotide used in RT-PCR experiments. RNA wasamplified with 803DFAM and 1894R; 803DFAM and 1385R; and 1506DFAM
and 1894R primers. B, (Top) Correlation between the percentage of the long
and the short RT-PCR amplification of TMEM16A exon 6b. (Bottom)
Correlation between the percentage of the long and the short RT-PCR
amplification of TMEM16A exon 15. Linear regression lines were fitted to the
data points obtained from the two amplification systems. Experimental
conditions were as described under Materials and Methods.
Additional file 3: Table S3. Clinicopathological variables in normal and
human breast cancer samples. 36 breast samples obtained by surgical
excision where divided in their normal (N) and tumor (T) portions.
Samples were classified in virtue of their histological evaluation (second
column), D defined as ductal breast or L defined as lobular breast
samples; grading (third column), necrosis (forth column) and receptors
(fifth, sixth, seventh and eighth column). ER, estrogen receptor; PgR,
progesterone receptor; Ki67, nuclear proliferation marker and HER2,
human epidermal growth factor receptor 2. The histological evaluation
showed 14 ductal and 3 lobular tumors and 1 ductal-bifasic. The majority
of tumors are positive for the estrogen and progesterone receptor
markers (15 and 13 tissues, respectively). The nuclear proliferation marker
Kit67 was low (+1 grading) in most tumors (n = 12) and high (grading +2
and +3) in 6 tumors. The HER2 marker was detected in 5 breast cancers.
Additional file 4: Figure S4. TMEM16A isoforms expression in stably
transfected HEK293 Flp- In cells. The inducible cell lines were either
untreated (left panel) or tetracycline treated (right panel) prior to
fluorescence measurement and examined by indirect immunofluorescence
analysis using a monoclonal antiserum against TMEM16A. Original
magnification, 4x. (Scale bars: 5 μm).
Additional file 5: Figure S5. Analysis of TMEM16A function in HEK293
cells. A, representative cell fluorescence traces showing quenching caused
by Ca2 + −dependent I- influx. The arrow shows the time of addition of the
solution containing high I—and the Ca2+ ionophore ionomycin. B,
summary of data obtained from multiple experiments. Each bar represents
the anion transport (TMEM16A) activity expressed as quenching rate (QR)
and calculated from the maximal slope of fluorescence decay.
Additional file 6: Figure S6. Splicing Coordination of TMEM16A mRNA
isoforms in normal adult human tissues. A, example of a positive (cervix)
and a negative (adipose tissues) case of SC. The top of the panel shows
the percentage of exon 6b inclusion in transcripts that include or exclude
exon 15. Lane 1: percentage of exon 15 inclusion considering all the four
isoforms. Lane 2: percentage of exon 15 inclusion in the isoforms that
contain only exon 6b. Lane 3: percentage of exon 15 inclusion in the
isoforms that lacks exon 6b. The identity of the isoforms considered in
each calculation is depicted below each lane. B, Percentage of exon 15
inclusion in transcripts that contain or lack exon 6b. Quantification of exon
15 inclusion associated to exon 6b inclusion or exclusion in 20 normal adult
human tissues. Statistically analysis was performed using paired Student’s t-
test. Ad = Adipose; Bl = Bladder; Cer = Cervix; Col = Colon; Eso = Esophagus;
He = Heart; Kid = Kidney; Liv = Liver; Ov = Ovary; Pla = Placenta; Pro =
Prostate; Int = Small Intestine; Spl = Spleen; Tes = Testes; Thym= Thymus;
Thyr = Thyroid; Tra = Trachea.
Additional file 7: Figure S7. Alternative Splicing Coordination of
TMEM16A in normal and breast cancer tissues. Quantification of exon 6b
inclusion associated to exon 15 inclusion or exclusion in normal and
breast cancer tissues. The former 18 samples are normal breast tissues,
the latter are the corresponding breast cancer tissues. The percentage is
expressed as means ± SD, based on at least three independent capillary
electrophoresis analyses.
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